-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a ...
-
A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
The goal of the study is to find out if a new drug called LBL-007, given in combination with other drugs called tislelizumab, bevacizumab, and ...
-
A Multi-phase Dose-Escalation followed by an Open-label Randomized Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) Chronic Myelomon
This study is testing a new drug called oral ASTX030 in people who have myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia ...
-
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
This study is designed for patients diagnosed with advanced NSCLC and other solid tumors with an ALK mutation. (NYU-Nuvalent NVL-655)
-
A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination with a PARP Inhibitor in Patients with BRCA 1/2 Mutant or Other HRD+ Advanced or Metastatic S
This study is split into two parts: Phase 1 and Phase 2. The study team is testing a new medicine, TNG348, for patients with tumors ...
-
A Phase 1/2 Randomized Study to Evaluate the Safety Tolerability Immunogenicity And Immunopersistence of a Clostridioides Difficile Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults
The purpose of this trial is to evaluate the safety and immune effects of an investigational vaccine in healthy volunteers ages 65 and older. This ...